Etrinabdione

DB18008InvestigationalSmall molecule

Etrinabdione: Overview.

Mechanism: Pharmacologically active on Cannabinoid receptor 2, Peroxisome proliferator-activated receptor gamma, and Prolyl hydroxylase EGLN2
Curator reviewed
Formula / weight: C₂₈H₃₅NO₃ · 433.592 g/mol (avg)
Also known as: (1'r,6'r)-3-(benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-(1,1'-bi(cyclohexane))-2',3,6-triene-2,5-dione · (1'r,6'r)-3-(benzylamino)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-(1,1'-bi(cyclohexane))-2',3,6-triene-2,5-dione · 2,5-cyclohexadiene-1,4-dione, 2-hydroxy-3-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-6-pentyl-5-((phenylmethyl)amino)-
Code names: EHP-101 · VCE-004 · VCE-004.8

Resolves to

Compound

Structure

InChIKeyNTGIXJASMBWXRO-JTHBVZDNSA-NSMILESCCCCCC1=C(NCC2=CC=CC=C2)C(=O)C([C@@H]2C=C(C)CC[C@H]2C(C)=C)=C(O)C1=O

Targets

What you can answer from here — as of July 08, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Etrinabdione, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.